



# Multimeric

Multimeric Biotherapeutics, Inc.

January 30, 2015

## **Multimeric Biotherapeutics Chief Scientific Officer to present at protein engineering conference in Boston, May 8, 2015**

SAN DIEGO, Jan. 30, 2015 – Multimeric Biotherapeutics, Inc. announced that its president and CSO Richard Kornbluth, MD, PhD, will give an invited presentation at during the annual meeting of “PEGS - The Essential Protein Engineering Summit” to be held in Boston at the Seaport World Trade Center, May 4-8, 2015. His presentation is scheduled during the sessions on May 7-8 devoted to “Agonist Immunotherapy Targets” for cancer immunotherapy. He will speak on May 8, 2015 at 2:10 PM on the topic.

Dr. Kornbluth’s talk is entitled, “Using the TNF Superfamily Ligands (TNFSF) as Many-Trimer Multimers for Vaccines and Cancer Immunotherapy.” The abstract for the presentation is:

“TNF superfamily ligands (TNFSF) are trimeric, Type II membrane proteins that can be released from the cell surface by proteolysis as soluble trimeric proteins. While the soluble trimer of TNF itself has some activities, most TNFSFs act by clustering their respective receptors on responding cells, which necessitates a multi-trimer arrangement for the TNFSF ligands. To mimic the natural cell surface array of TNFSFs, we have developed fusion proteins consisting of TNFSF extracellular domains joined to self-assembling multimerizing scaffolds based on Acrp30 or surfactant protein D (SPD). The resulting 2- and 4-trimer soluble TNFSFs have high activity both in vitro and in vivo. Four immunologically active, multi-trimer TNFSFs will be highlighted: CD40L, 4-1BBL, OX40L, and GITRL.”

PEGS - The Essential Protein Engineering Summit is the premier event for antibody and protein science research and the biologics industry, with more than 1,800 participants in attendance from over 30 countries. Join us in Boston this May 4-8, 2015 to share insight and best practices with colleagues, connect and form new collaborations during copious networking opportunities, learn from world-renowned thought leaders, discover industry trends and find solutions to current challenges. PEGS is knowledge-sharing at its best.

About Multimeric Biotherapeutics, Inc.

Multimeric Biotherapeutics, Inc. (“Multimeric”) was formed around technology invented by Dr. Richard Kornbluth when he was at the University of California San Diego. This provides for multi-trimer forms of the TNF SuperFamily (TNFSF) ligands called MegaLigands™ and UltraLigands™. Current products under development are MegaOX40™ for cancer immunotherapy, MegaCD40L™ as a vaccine adjuvant and cancer immunotherapy agent, and Ultra4-1BBL™ for growing anti-tumor T cells in vitro. The company has received funding from its founders, angel investors, and NIH grants. It operates out of fully equipped laboratory space in the San Diego Science Center. For more information, please visit the company website at [www.multimericbio.com](http://www.multimericbio.com)